Understanding Real World Use of a protein tyrosine kinase inhibitor (TKI) in CML
Background | St Mark’s hospital in NW london is a world leading centre for the management of Inflammatory Bowel Disease (IBD). Service over capcity and under severe pressure to deliver, particularly with the advant of NICE guidance recommending biologics for the treatment of ulcerative colitis. Client with a biologic treatment for inflammatory bowel disease (IBD), wanted to support NHS centre in understanding service offered for management of patients. Understanding on all parts with any service optimisation needs data to support the case for change within Trust. |
RWD Solution | Mixed methodogy service evaluation developed with all NHS stakeholders. Evaluation involved retrospective patient-level data collection to describe patient pathway, prospective clinic-level data collection to describe patient mix and service delivery, evaluation of staff and patient satisfication with service. |
Outputs |
|
Related posts